Cargando…
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to pr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074336/ https://www.ncbi.nlm.nih.gov/pubmed/32012726 http://dx.doi.org/10.3390/jcm9020346 |
_version_ | 1783506810705018880 |
---|---|
author | Caro-Ordieres, Teresa Marín-Royo, Gema Opazo-Ríos, Lucas Jiménez-Castilla, Luna Moreno, Juan Antonio Gómez-Guerrero, Carmen Egido, Jesús |
author_facet | Caro-Ordieres, Teresa Marín-Royo, Gema Opazo-Ríos, Lucas Jiménez-Castilla, Luna Moreno, Juan Antonio Gómez-Guerrero, Carmen Egido, Jesús |
author_sort | Caro-Ordieres, Teresa |
collection | PubMed |
description | Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs. |
format | Online Article Text |
id | pubmed-7074336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70743362020-03-20 The Coming Age of Flavonoids in the Treatment of Diabetic Complications Caro-Ordieres, Teresa Marín-Royo, Gema Opazo-Ríos, Lucas Jiménez-Castilla, Luna Moreno, Juan Antonio Gómez-Guerrero, Carmen Egido, Jesús J Clin Med Review Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs. MDPI 2020-01-27 /pmc/articles/PMC7074336/ /pubmed/32012726 http://dx.doi.org/10.3390/jcm9020346 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Caro-Ordieres, Teresa Marín-Royo, Gema Opazo-Ríos, Lucas Jiménez-Castilla, Luna Moreno, Juan Antonio Gómez-Guerrero, Carmen Egido, Jesús The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title | The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title_full | The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title_fullStr | The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title_full_unstemmed | The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title_short | The Coming Age of Flavonoids in the Treatment of Diabetic Complications |
title_sort | coming age of flavonoids in the treatment of diabetic complications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074336/ https://www.ncbi.nlm.nih.gov/pubmed/32012726 http://dx.doi.org/10.3390/jcm9020346 |
work_keys_str_mv | AT caroordieresteresa thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT marinroyogema thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT opazorioslucas thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT jimenezcastillaluna thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT morenojuanantonio thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT gomezguerrerocarmen thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT egidojesus thecomingageofflavonoidsinthetreatmentofdiabeticcomplications AT caroordieresteresa comingageofflavonoidsinthetreatmentofdiabeticcomplications AT marinroyogema comingageofflavonoidsinthetreatmentofdiabeticcomplications AT opazorioslucas comingageofflavonoidsinthetreatmentofdiabeticcomplications AT jimenezcastillaluna comingageofflavonoidsinthetreatmentofdiabeticcomplications AT morenojuanantonio comingageofflavonoidsinthetreatmentofdiabeticcomplications AT gomezguerrerocarmen comingageofflavonoidsinthetreatmentofdiabeticcomplications AT egidojesus comingageofflavonoidsinthetreatmentofdiabeticcomplications |